Not Signed In -
Vaccine Safety: Data-Sharing Process |
|
|
Clinical Trial: Safety, Tolerability, and Immunogenicity of an Investigational Vaccine with Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age
This study is no longer recruiting patients.
|
Purpose
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Measles Mumps Rubella Varicella | Vaccine: Investigational Vaccine | Phase II Phase III |
MedlinePlus related topics: Chickenpox; Measles; Mumps; Rubella
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Safety Study
Eligibility
Ages Eligible for Study: 12 Months - 18 Months, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Healthy children 12 to 18 months of age
Exclusion Criteria:
- History or prior exposure to measles, mumps, or rubella
- History of allergic reactions to any component of the vaccines as evaluated by the study doctor
More Information
Study ID Numbers: 2004_074
Record last reviewed: September 2004
Last Updated: October 25, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092404
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: September 2004
Last Updated: October 25, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092404
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
